Harskamp Ralf E, Halkos Michael E, Xian Ying, Szerlip Molly A, Poston Robert S, Mick Stephanie L, Lopes Renato D, Tijssen Jan G, de Winter Robbert J, Peterson Eric D
Duke Clinical Research Institute, Durham, NC; Academic Medical Center-University of Amsterdam, Amsterdam, The Netherlands.
Emory University, Atlanta, GA.
Am Heart J. 2015 Apr;169(4):557-63.e6. doi: 10.1016/j.ahj.2015.01.003. Epub 2015 Jan 7.
Hybrid coronary revascularization (HCR) combines a surgical and percutaneous approach for treatment of multivessel coronary artery disease.
A survey was conducted among 200 cardiologists and cardiac surgeons from 100 top-ranked US hospitals. Questions were asked involving the perception, experience, and future expectations of HCR.
Of physicians invited to the survey, 90 completed the survey (45.5%). Relative to nonresponders, responders were more often affiliated with an academic institution (80.0% vs 61.8%, P=.005), with higher patient volumes, and with the availability of a hybrid operating room (90.0% vs 67.3%, P<.001). Survey responders felt that HCR should be considered in an older and relatively healthy patient population without complex lesions. Cardiac surgeons were more favorable to use HCR in patients with chronic lung disease (42.0% vs 10.0%, P<.001) or renal failure (28.0% vs 15.0%, P=.06). Among responders with HCR experience (n=54), 94% reported good to excellent results, and the learning curve differed depending on the surgical technique used. Inappropriate patient selection (41.2%) was the most common cause for complications. Three-quarter of responders believe that the future role for HCR will expand in the next decade. Important determinants of greater HCR use in the future were collaborative associations between cardiac surgeons and cardiologists (86.7%), appropriate patient selection (67.8%), and the outcomes of ongoing clinical trials (57.8%).
In this nationwide survey, cardiologists and cardiac surgeons felt that HCR is a reasonable alternative technique for coronary revascularization among suitable patients. Most felt that use of HCR would increase in the next decade.
杂交冠状动脉血运重建术(HCR)结合了外科手术和经皮介入方法来治疗多支冠状动脉疾病。
对来自美国100家顶级医院的200名心脏病专家和心脏外科医生进行了一项调查。询问了有关HCR的认知、经验和未来期望的问题。
受邀参与调查的医生中,90人完成了调查(45.5%)。与未回复者相比,回复者更常隶属于学术机构(80.0%对61.8%,P = 0.005),患者量更大,且拥有杂交手术室(90.0%对67.3%,P<0.001)。调查回复者认为,对于年龄较大且相对健康、无复杂病变的患者群体,应考虑采用HCR。心脏外科医生更倾向于在患有慢性肺病(42.0%对10.0%,P<0.001)或肾衰竭(28.0%对15.0%,P = 0.06)的患者中使用HCR。在有HCR经验的回复者中(n = 54),94%报告结果良好至优秀,且学习曲线因所采用的手术技术而异。患者选择不当(41.2%)是并发症的最常见原因。四分之三的回复者认为,HCR在未来十年的作用将会扩大。未来更多使用HCR的重要决定因素是心脏外科医生和心脏病专家之间的合作关系(86.7%)、合适的患者选择(67.8%)以及正在进行的临床试验结果(57.8%)。
在这项全国性调查中,心脏病专家和心脏外科医生认为,对于合适的患者,HCR是冠状动脉血运重建的一种合理替代技术。大多数人认为,HCR在未来十年的使用将会增加。